Mumps-Parotitis Virus IgM Control Serum BC103M

$94.00

Summary

Virion/Serion Diagnostic Kit Control for research use (RUO)
Mumps-Parotitis Virus IgM Control Serum
Applications: ELISA
IgM control serum
Ready-to-use; pre-diluted for SERION ELISA classic and SERION ELISA antigen assays
3 mL

SKU: BC103M Categories: control serum, Virion/Serion kits Tags: ELISA control serum, IgM, Mumps Virus

Weight	1 lbs
Dimensions	9 × 5 × 2 in
target	Mumps/Parotitis Virus reactive IgM
species reactivity	Mumps Virus
applications	ELISA
assay type	Indirect & quantitative
available size	3 mL

Mumps-Parotitis Virus IgM Control Serum BC103M

kit
Research area Infectious Disease
Storage Store at 2-8°C.
Associated products Mumps Virus Nucleoprotein Control Antigen (BA103R01) Mumps Virus Antigen (BA103VS) Mumps/Parotitis Virus IgG Control Serum (BC103G) Mumps/Parotitis Virus IgM Control Serum (BC103M) Mumps Virus IgG ELISA Kit (ESR103G) Mumps Virus IgM ELISA Kit (ESR103M)

target relevance

human antibody anti-Mumps Virus

Mumps Virus

Description
Virus that causes mumps (epidemic parotitis)

Structure
Mumps virus is an enveloped, negative-sense, single-stranded RNA virus belonging to the genus Orthorubulavirus within the family Paramyxoviridae. Humans are the only known natural host of the virus. The viral particle is surrounded by a lipid envelope containing surface glycoproteins responsible for attachment to and entry into host cells. Mumps virus is transmitted primarily through respiratory droplets, saliva, and direct contact with infected individuals. Following infection, the virus initially replicates in the upper respiratory tract and regional lymphoid tissues before spreading through the bloodstream to multiple organs, particularly the salivary glands, testes, ovaries, pancreas, and central nervous system. Although widespread vaccination has significantly reduced the incidence of mumps in many countries, outbreaks continue to occur, particularly in settings involving close contact such as schools, universities, and military facilities.

Diagnosis
The diagnosis of mumps virus infection is performed through serological and molecular methods. Detection of mumps-specific IgM antibodies by ELISA is commonly used to support the diagnosis of recent infection, while IgG testing may be used to assess immune status or prior exposure. Reverse transcription polymerase chain reaction (RT-PCR) is the preferred method for laboratory confirmation and allows sensitive detection of viral RNA in buccal swabs, saliva, cerebrospinal fluid, and other clinical specimens. Viral culture may be performed in specialized laboratories but is less commonly used due to the availability of rapid molecular techniques. Laboratory confirmation is particularly important because mumps can resemble other causes of parotitis and viral illness.

Symptoms
Mumps virus infection typically develops following an incubation period of approximately twelve to twenty-five days. Early symptoms commonly include fever, headache, fatigue, muscle aches, loss of appetite, and malaise. The most characteristic feature of the disease is painful swelling of one or both parotid salivary glands, resulting in facial swelling and tenderness near the jaw and ears. Additional salivary glands may also be affected. While many infections are mild or asymptomatic, complications can occur and may include orchitis, epididymitis, oophoritis, mastitis, pancreatitis, meningitis, encephalitis, and hearing loss. In post-pubertal males, orchitis may occasionally result in testicular atrophy and impaired fertility. Although most patients recover completely, severe neurological complications can occur in rare cases.

Data

FAQ & Publications

Frequently Asked Questions

What is the intended application for the Mumps-Parotitis Virus IgM Control Serum BC103M?

This control serum is designed for use in ELISA assays, specifically compatible with SERION ELISA classic and SERION ELISA antigen assays to detect Mumps-Parotitis Virus reactive IgM antibodies.

How should the Mumps-Parotitis Virus IgM Control Serum BC103M be stored to maintain its stability?

The serum should be stored at a temperature of 2-8°C to preserve its integrity and performance.

Is the Mumps-Parotitis Virus IgM Control Serum BC103M ready to use or does it require dilution?

The control serum is provided as ready-to-use and is pre-diluted for use in the specified SERION ELISA assays.

What is the species reactivity of the Mumps-Parotitis Virus IgM Control Serum BC103M?

This control serum is reactive to the Mumps Virus, making it suitable for research involving this particular infectious agent.

What volume is supplied for the Mumps-Parotitis Virus IgM Control Serum BC103M, and is it suitable for quantitative assays?

The product is supplied as a 3 mL volume and is intended for indirect and quantitative ELISA assay formats.

Publications

pmid	title	authors	citation
We haven't added any publications to our database yet.

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from the PubMed database provided by the United States National Library of Medicine at the National Institutes of Health.

Protocols

relevant to this product
BC103M protocol

Documents

#
Please enter your product and batch number here.

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.

Mumps-Parotitis Virus IgM Control Serum BC103M

Data

FAQ & Publications

Protocols

Documents

Related Technical Resources & Posts

Reviews

Related Products

Enterovirus IgM Control Serum BC133M

Candida albicans IgM Control Serum BC117M

Influenza B Virus IgM Control Serum BC1232M

Campylobacter jejuni IgM Control Serum BC139M

Influenza A Virus IgM Control Serum BC1231M

Brucella IgM Control Serum BC116M

Helicobacter pylori IgM Control Serum BC118M

Borrelia burgdorferi IgM Control Serum BC121M

Aspergillus fumigatus IgM Control Serum BC132M

Echovirus IgM Control Serum BC135M

Cytomegalovirus IgM Control Serum BC109M

Coxsackie IgM Virus Control Serum BC134M

Coxiella burnetii Phase 2 IgM Control Serum BC1312M

Chlamydia trachomatis IgM Control Serum BC1372M

Chlamydia pneumoniae IgM Control Serum BC1371M